Acorda Therapeutics, Inc.

OTCPK:ACOR.Q Stock Report

Market Cap: US$37.4k

Acorda Therapeutics Management

Management criteria checks 2/4

Acorda Therapeutics' CEO is Ron Cohen, appointed in Jan 1995, has a tenure of 29.58 years. total yearly compensation is $996.33K, comprised of 62.7% salary and 37.3% bonuses, including company stock and options. directly owns 0.6% of the company’s shares, worth $225.39. The average tenure of the management team and the board of directors is 6.3 years and 21.1 years respectively.

Key information

Ron Cohen

Chief executive officer

US$996.3k

Total compensation

CEO salary percentage62.7%
CEO tenure29.6yrs
CEO ownership0.6%
Management average tenure6.3yrs
Board average tenure21.1yrs

Recent management updates

Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

May 26
Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

Recent updates

Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?

Feb 21
Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement

Dec 18
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement

Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?

Jun 05
Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?

Acorda wins $16.5M in Ampyra arbitration case with Alkermes

Oct 17

Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on vote

Oct 10

Acorda inks license deal with Asieris for pre-clinical drug

Aug 29

Acorda Therapeutics announces resignation of COO

Aug 19

Acorda Therapeutics: Managing The Transition

Oct 04

Acorda Therapeutics Continues To Maneuver For A Turnaround

Jul 24

CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action

Jun 17

Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

May 26
Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

Acorda Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts

Mar 09
Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts

CEO Compensation Analysis

How has Ron Cohen's remuneration changed compared to Acorda Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$263m

Dec 31 2023US$996kUS$625k

-US$253m

Sep 30 2023n/an/a

-US$16m

Jun 30 2023n/an/a

-US$21m

Mar 31 2023n/an/a

-US$58m

Dec 31 2022US$984kUS$625k

-US$66m

Sep 30 2022n/an/a

-US$106m

Jun 30 2022n/an/a

-US$119m

Mar 31 2022n/an/a

-US$95m

Dec 31 2021US$2mUS$743k

-US$104m

Sep 30 2021n/an/a

-US$166m

Jun 30 2021n/an/a

-US$132m

Mar 31 2021n/an/a

-US$127m

Dec 31 2020US$2mUS$796k

-US$100m

Sep 30 2020n/an/a

US$49m

Jun 30 2020n/an/a

-US$222m

Mar 31 2020n/an/a

-US$232m

Dec 31 2019US$2mUS$796k

-US$273m

Sep 30 2019n/an/a

-US$329m

Jun 30 2019n/an/a

-US$79m

Mar 31 2019n/an/a

-US$6m

Dec 31 2018US$2mUS$796k

US$34m

Sep 30 2018n/an/a

-US$147m

Jun 30 2018n/an/a

-US$158m

Mar 31 2018n/an/a

-US$213m

Dec 31 2017US$2mUS$792k

-US$223m

Compensation vs Market: Ron's total compensation ($USD996.33K) is above average for companies of similar size in the US market ($USD689.66K).

Compensation vs Earnings: Ron's compensation has increased whilst the company is unprofitable.

CEO

Ron Cohen (68 yo)

29.6yrs

Tenure

US$996,328

Compensation

Dr. Ron Cohen, M.D., serves as an Independent Director of ZWI Therapeutics, Inc. since January 2024. He has been the Founder of Acorda Therapeutics, Inc. since 1995 and has been its Chief Executive Officer...

Leadership Team

NamePositionTenureCompensationOwnership
Ron Cohen
Founder29.6yrsUS$996.33k0.60%
$ 225.4
Michael Gesser
CFO & Treasurer2.8yrsUS$611.55k0%
$ 0
Neil Belloff
General Counsel & Corporate Secretary2.8yrsUS$661.57k0%
$ 0
Denise Duca
Executive Vice President of Human Resources9.6yrsno datano data
Kerry Clem
Chief Commercial Officer2.9yrsUS$592.23k0.041%
$ 15.2
Sofia Ali
Senior VP of Operations & Strategic Planningno datano datano data
Susan Way
Senior VP of Drug Development & Regulatory Affairsno datano datano data
Wise Young
Special Scientific Advisorno dataUS$10.00kno data

6.3yrs

Average Tenure

64yo

Average Age

Experienced Management: ACOR.Q's management team is seasoned and experienced (6.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ron Cohen
Founder29.6yrsUS$996.33k0.60%
$ 225.4
John Varian
Independent Director2.6yrsUS$94.71k0%
$ 0
Carl Cotman
Member of Scientific Advisory Boardno datano datano data
Sandra Panem
Independent Director26.6yrsUS$82.65k0.0019%
$ 0.7
Mark Tuszynski
Member of Scientific Advisory Boardno datano datano data
Melitta Schachner
Member of Scientific Advisory Boardno datano datano data
Patrick Tresco
Member of Scientific Advisory Boardno datano datano data
Stephen Waxman
Member of Scientific Advisory Boardno datano datano data
Mary Bunge
Member of Scientific Advisory Boardno datano datano data
James Fawcett
Member of Scientific Advisory Boardno datano datano data
Michael Beattie
Member of Scientific Advisory Boardno datano datano data
John Kelley
Independent Non-Executive Chairman15.7yrsUS$140.22k0%
$ 0

21.1yrs

Average Tenure

70yo

Average Age

Experienced Board: ACOR.Q's board of directors are seasoned and experienced ( 21.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/08/13 18:19
End of Day Share Price 2024/08/13 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Acorda Therapeutics, Inc. is covered by 28 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert LeBoyerAegis Capital Corporation
Christopher RaymondBaird
John NewmanCanaccord Genuity